The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
IMS 2025 | Managing toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma
Andrew Yee, MD, Massachusetts General Hospital Cancer Center, Boston, MA, comments on the management of toxicities associated with BCMA-targeting bispecific antibodies in multiple myeloma. Dr Yee notes that while these toxicities are relatively new to manage, increasing familiarity with these therapies will lead to a safer and more feasible treatment approach. This interview took place at the 22nd International Myeloma Society (IMS) Annual Meeting in Toronto, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
BCMA therapies, they’re powerful drugs for our patients with great efficacy. But there are a couple of things to be aware of when giving these drugs. Some of the toxicities to be aware of are cytokine release syndrome and risk of neurotoxicity. And these are relatively new toxicities for oncologists to manage. But I think with time and with all therapies, I think practitioners, we have more familiarity with giving these therapies...
BCMA therapies, they’re powerful drugs for our patients with great efficacy. But there are a couple of things to be aware of when giving these drugs. Some of the toxicities to be aware of are cytokine release syndrome and risk of neurotoxicity. And these are relatively new toxicities for oncologists to manage. But I think with time and with all therapies, I think practitioners, we have more familiarity with giving these therapies. Now, because of the risk of cytokine release syndrome, it’s important for all the players involved who are taking care of these patients to be aware of that specific toxicity profile so that they’re ready to manage these patients. For example, if they get a phone call about them overnight or if they show up in the emergency room or if they’re hospitalized. But because of this toxicity, while it is a new therapy, I think with all things, I think with increasing comfort level, I think this can be done in a very safe and feasible manner. So I think at first it can be a little bit daunting, but I think with time and as practitioners get more experience with bispecific antibodies in general, I think this will be part of a routine part of patient care where it won’t be perceived as being so unique anymore.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Disclosures: Consultant for multiple companies.
